What to consider when conducting a cost-effectiveness analysis in a clinical setting

被引:7
|
作者
Naglak, M
Mitchell, DC
Kris-Etherton, P
Harkness, W
Pearson, TA
机构
[1] W Chester Univ, Dept Hlth, W Chester, PA 19380 USA
[2] Penn State Univ, Dept Nutr, University Pk, PA 16802 USA
[3] Penn State Univ, Diet Assessment Serv, University Pk, PA 16802 USA
[4] Penn State Univ, Dept Nutr, University Pk, PA 16802 USA
[5] Penn State Univ, Dept Stat, University Pk, PA 16802 USA
[6] Univ Rochester, Dept Community & Prevent Med, Rochester, NY USA
[7] Mary Imogene Bassett Res Inst, Cooperstown, NY USA
[8] Columbia Univ, Cooperstown, NY USA
关键词
D O I
10.1016/S0002-8223(98)00266-1
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
More data are needed providing strong evidence that nutrition services are cost-effective. Economic evaluations, such as cost-effectiveness analyses, are excellent practice-based research projects. We conducted a cost-effectiveness analysis in a clinical setting to compare the cost-effectiveness of lipid-lowering medications plus diet therapy (medication+diet) with diet therapy alone (diet alone) for treating patients with hypercholesterolemia. Twenty-five adults with hypercholesterolemia (13 receiving medication+diet, 12 receiving diet alone) either participated in an 8-week, home-based, step 1 intervention or were counseled about diet and lifestyle by their care provider. Diet, cost, and laboratory data were collected at baseline, at 9 months, and at 19 months after participation in the intervention (follow-up). Cost per unit change in outcome was evaluated for each group. The diet-alone group made only small changes in dietary Intake, changes that were smaller in magnitude than those made by the medication+diet group. Nevertheless, at 9 months, costs per unit change in total serum cholesterol level and low-density lipoprotein cholesterol (LDL-C) level were approximately $24 and $83 less, respectively, for the diet-alone group. At follow-up, however, the cost per unit change in LDL-C level was approximately $17 less for the medication+diet group, which can be explained by the medication+diet group's greater decrease in LDL-C level. The following elements should be considered when conducting a cost-effectiveness analysis of medical nutrition therapy: effectiveness of the nutrition intervention, adequate sample size, confounding variables, compliance with diet and drug therapy, direct and indirect costs of care, and follow-up evaluation.
引用
收藏
页码:1149 / 1154
页数:6
相关论文
共 50 条
  • [21] What are the "costs" of cost-effectiveness?
    Ferraris, Victor A.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (04): : 1682 - 1683
  • [22] Cost-effectiveness analysis: What neurologists should know
    Holloway, RG
    NEUROLOGIST, 1996, 2 (06) : 365 - 373
  • [23] EXPENSIVE COMPARED TO WHAT - A CRITIQUE OF COST-EFFECTIVENESS ANALYSIS
    HIMMELSTEIN, DU
    WOOLHANDLER, S
    CLINICAL RESEARCH, 1985, 33 (02): : A254 - A254
  • [24] Cost-effectiveness analysis: What is it and how will it influence neurology
    Holloway, RG
    ANNALS OF NEUROLOGY, 1996, 39 (06) : 818 - 823
  • [25] The Cost-Effectiveness of rFVIIIFc in a Swedish Setting
    Schlueter, M.
    Henry, N.
    Jovanovic, J.
    Lowin, J.
    Krishnan, S.
    Myren, K. -J.
    HAEMOPHILIA, 2016, 22 : 75 - 75
  • [26] AN ANALYSIS OF HOW NOT TO USE COST-EFFECTIVENESS ANALYSIS FOR PRICE-SETTING
    Standaert, B.
    Ethgen, O.
    Emerson, R. A.
    Postma, M. J.
    VALUE IN HEALTH, 2013, 16 (07) : A616 - A616
  • [27] Re: An alternative cost-effectiveness analysis of ThinPrep in the Australian setting
    Llewellyn, H
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2006, 46 (01): : 67 - 67
  • [28] WILL COST-EFFECTIVENESS ANALYSIS WORSEN THE COST-EFFECTIVENESS OF CARE
    HIMMELSTEIN, DU
    WOOLHANDLER, S
    BOR, DH
    CLINICAL RESEARCH, 1987, 35 (03): : A744 - A744
  • [29] Cervical cancer screening in the Philippine setting: A cost-effectiveness analysis
    Ngelangel, CA
    Limson, GM
    Fajutrao, LB
    Cordero, CP
    Javelosa, MA
    Festin, MR
    Ramiro, LS
    Llave, CL
    Abelardo, AD
    VALUE IN HEALTH, 2003, 6 (03) : 230 - 230
  • [30] Cost-effectiveness analysis of the diabetes prevention program in a Spanish setting
    Palmer, AJ
    Roze, S
    Valentine, WJ
    Renaudin, C
    VALUE IN HEALTH, 2004, 7 (06) : 741 - 741